louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06377618: Comparison Of Resistance Training And Core Strengthening Exercises Vitamin D In Postmenopausal Women With Low Back Pain
Official title: Comparison Of Resistance Training And Core Strengthening Exercises Along With Vitamin D Intake In Postmenopausal Women With Low Back Pain
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Menopausal
Pain, Low Back
Lead sponsor: Superior University
Sponsor class: OTHER
First posted: 2024-04-22
Enrollment: 36
Sex: FEMALE
Minimum age (years): 50
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: This study aims to evaluate the effectiveness of resistance training, core strengthening exercises, and vitamin D supplementation in reducing low back pain (LBP) among postmenopausal women.

Detailed description: Postmenopausal women are particularly susceptible to LBP due to physiological changes such as reduced estrogen levels, decreased muscle mass, and bone density. The randomized controlled trial (RCT) will be conducted over six months in various clinical settings in Lahore, with a sample size of 36 participants, divided into two groups. The inclusion criteria focus on postmenopausal women aged 50-70 years experiencing LBP for at least three months and who are not currently taking vitamin D supplements. Data on pain intensity, functional disability, muscle strength, endurance, and vitamin D levels will be collected and analyzed to assess the interventions' impact. The study's findings could provide evidence-based recommendations for managing LBP in postmenopausal women, combining physical activity with nutritional supplementation.

Eligibility criteria: Inclusion Criteria:

* Postmenopausal women aged 50-70 years.
* Experiencing low back pain for at least 3 months.
* Capable of engaging in light to moderate physical exercise.

Exclusion Criteria:

* History of spinal surgery.
* currently taking vitamin D supplements.
* Diagnosed with severe osteoporosis.
* Chronic use of pain medication that cannot be temporarily ceased.
* Current participation in another clinical trial.

Primary outcomes:
measure: Visual Analog Scale (VAS)
timeFrame: 6 Month
measure: Oswestry Disability Index (ODI)
timeFrame: 6 Months
Secondary outcomes:
Other outcomes:
Locations:
city: Lahore
country: Pakistan
facility: Azra Naheed Medical College, Superior University
state: Punjab
Study officials:
References:
Clinical trial NCT06272318: Vital Signs Blood Pressure Trial
Official title: Vital Signs Blood Pressure Trial
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Cardiovascular Diseases
Hypertension
Blood Pressure
Lead sponsor: Stanford University
Sponsor class: OTHER
First posted: 2024-02-22
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 64
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Participants with a range of health conditions are needed for this study, including those with cardiac or blood pressure issues, as well as individuals who are considered healthy.

Brief summary: The purpose of this study is collect subject vitals with a blood pressure cuff, electrocardiogram (ECG), and photoplethysmogram (PPG). This data can then be used to develop a reliable, accurate, noninvasive, and continuous blood pressure monitoring device.


Eligibility criteria: Inclusion Criteria:

* Age \>17 and \<65 years
* BMI \>20 and \<35

Exclusion Criteria:

* Age \<18 or \>64
* BMI \<20 or \>35
* Pregnancy

Primary outcomes:
measure: Collection of Subject Name (optional)
timeFrame: Less than 1 minute
measure: Collection of Subject Height
timeFrame: Less than 1 minute
measure: Collection of Subject Weight
timeFrame: Less than 1 minute
measure: Collection of Subject Age
timeFrame: Less than 1 minute
measure: Collection of Subject Medical Comorbidities
timeFrame: 1 minute
measure: Systolic and Diastolic Blood Pressure Measurement
timeFrame: 1-2 minutes
measure: Collection of ECG Waveforms
timeFrame: 5 minutes
measure: Collection of PPG Waveforms
timeFrame: 5 minutes
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00961818: Immediate Effect Analysis of Vocal Techniques
Official title: Perceptual, Acoustic and Laryngological Analysis of Vocal Techniques Immediate Effect
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Voice Disorders
Keywords: Voice
Voice Quality
Voice Training
Evaluation
Lead sponsor: Tuiuti University of Paraná
Sponsor class: OTHER
First posted: 2009-08-19
Enrollment: 32
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Were included in the study, female subjects with normal voices evidenced by the slightly altered auditory-perceptual analysis, without vocal complaints, aged between 20 and 45 years.

Brief summary: The objective of this clinical and experimental study was to verify the immediate effect of vocal techniques: vibration, nasal sound and articulation in women without vocal complaints.

Detailed description: Vocal techniques have been used, but few studies had as their aim to effectively verify its use and effect produced in voice and the larynx. The objective of this clinical and experimental study was to verify the immediate effect of vocal techniques: vibration, nasal sound and articulation. Material and method: 32 female subjects with normal to mild dysphonia participated in the research, with ages from 20 to 45 years. All subjects were submitted to realization of vocal techniques of vibration of the lips, articulation and nasal sounds for twenty minutes. The subjects were submitted to record the voice and laryngostroboscopic exams for perceptual analysis and laryngostroboscopic exams before and after the use of vocal techniques.

Eligibility criteria: Inclusion Criteria:

* female subjects
* with normal voices or slightly altered voice
* without vocal complaints

Exclusion Criteria:

* subject with altered voices of moderate and severe grades
* with lesions in the vocal folds; fusiform or double gap on the phonation
* subjects with neurological disorders
* subjects who had been treated earlier speech by voice changes and / or surgery in the larynx

Primary outcomes:
measure: Subjects were submitted to perceptual analysis and laryngostroboscopic exams before and after the use of vocal techniques.
timeFrame: twenty minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Curitiba
country: Brazil
facility: Tuiuti of Paraná University
state: Parana
Study officials:
affiliation: Tuiuti of Parana University
name: Eliane C. Pereira, Master
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00604318: Quality of Life, Recombinant TSH (Thyrogen) and Thyroid Cancer
Official title: Is it Possible to Increase Quality of Life, Using Recombinant TSH Instead of Withdrawal of Thyroid Hormone Treatment, Before Iodine Uptake in Patients With Thyroid Cancer?
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Thyroid Cancer
Keywords: quality of life
Lead sponsor: Copenhagen University Hospital at Herlev
Sponsor class: OTHER
Collaborators: name: Odense University Hospital
First posted: 2008-01-30
Enrollment: 56
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: To evaluate quality of life in patients after 10 days pause of thyroid medication (Liothyronine) compared to treatment with recombinant TSH (Thyrogen) before radioiodine uptake and treatment in a double-blinded, randomised cross-over design.

Detailed description: Patients with a thyroid follicular or papillary cancer referred to radioiodine treatment in oncological department . The patients after thyroidectomy will be treated with Liothyronine and this treatment will be paused 10 days before radioiodine. As a routine these patients will be re-evaluated with iodine uptake 4 months later.

The patients will be randomised to either T3 pause related to the first radioiodine treatment and Thyrogen injection (recombinant TSH) related to the second treatment/uptake - or Thyrogen related to the first treatment and T3 pause related to the second treatment /uptake.

All medication given in the 10 days period right before radioiodine treatment/uptake will be delivered to the patients and marked with a protocol number. In the period with T3 pause the patients will be given placebo tablets and an injection of saline (instead of Thyrogen) before treatment/uptake at the similar time as given the Thyrogen injection. A nurse otherwise not involved in the study will give the injection.

Patients will be evaluated by VAS, SF-36, and Eortc QLC30 (version 2.0) before radioiodine treatment and 3 weeks after treatment.

Eligibility criteria: Inclusion Criteria:

* Follicular or papillary thyroid cancer

Exclusion Criteria:

* \< 18 or \> 75 years old
* Pregnant or lactating women

Primary outcomes:
measure: quality of life
timeFrame: month
Secondary outcomes:
Other outcomes:
Locations:
city: Herlev
country: Denmark
facility: Dept of Oncology, Herlev Hospital
Study officials:
affiliation: dept of endocrinology,Herlev Hospital
name: Birte Nygaard, Md, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT05166018: Optimization of a Tool for Predicting Postoperative Clinical Evolution After Lumbar Surgery
Official title: Optimization of a Tool for Predicting Postoperative Clinical Evolution After Lumbar Surgery Multicenter Longitudinal Prospective Study on a National Cohort Clinical Evolution After Lumbar Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Spine Disease
Spinal Fusion
Surgery
Spine Degeneration
Lead sponsor: Cortexx Medical Intelligence
Sponsor class: INDUSTRY
Collaborators: name: Ramsay Générale de Santé
name: Elsan
name: Malakoff-Humanis
First posted: 2021-12-21
Enrollment: 119
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: The patient will be required to complete a guided digital questionnaire at each follow-up assessment.

This questionnaire will be completed online by the patient in the Surgery Medical Outcomes (SuMO system) system developped by the Society Cortexx Medical Intelligence. The system access procedures and connection codes will be known to the patient by the investigating physician. Patients will, throughout the study, be automatically informed via the SUMO system of the availability of data to be completed. The security of patient data is guaranteed by encrypted and separate storage of medical data, in order to comply with applicable regulatory requirements.
Primary purpose: DIAGNOSTIC

Brief summary: The objective of the study is the establishment, optimization and prospective evaluation of a digital predictive platform capable of providing for each lumbar spine operated patient a clinical predictive status: Patient green (success) orange (treatment failure ), red patient (complication) in order to optimize his medical care up to 6 months.


Eligibility criteria: Inclusion Criteria:

* Major patient
* Eligible for lumbar decompression surgery, instrumented or not
* Social insured
* Having given consent
* Eligible for the acts described in Protocole

Exclusion Criteria:

* Minor
* Pregnant or breastfeeding woman
* Safeguard measure or guardianship
* Arthrodesis on more than 2 levels
* Interventions linked to a traumatic or infectious context are excluded

Primary outcomes:
measure: Optimization of a tool for predicting the postoperative clinical course after lumbar surgery
timeFrame: 14 months
Secondary outcomes:
measure: Collection of optimized data in the patient operative long terms care
timeFrame: 14 months
Other outcomes:
Locations:
city: Bruges
country: France
facility: Polyclinique Jean Villar
state: Nouvelle Aquitaine
city: Paris
country: France
facility: Clinique Geoffroy Saint-Hilaire
Study officials:
References:
citation: Andre A, Peyrou B, Carpentier A, Vignaux JJ. Feasibility and Assessment of a Machine Learning-Based Predictive Model of Outcome After Lumbar Decompression Surgery. Global Spine J. 2022 Jun;12(5):894-908. doi: 10.1177/2192568220969373. Epub 2020 Nov 19.
Clinical trial NCT04763018: Study of External Neuromodulation to Improve Signs and Symptoms of Dry Eye in Visual Display Terminal Users
Official title: A Randomized Sham Controlled Study of External Neuromodulation to Improve Signs and Symptoms of Dry Eye in Visual Display Terminal Users
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Visual Display Users With Previously Undiagnosed Dry Eye
Lead sponsor: Olympic Ophthalmics, Inc.
Sponsor class: INDUSTRY
First posted: 2021-02-21
Enrollment: 35
Sex: ALL
Minimum age (years): 18
Maximum age (years): 69
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: Day 14-30, all subjects receive therapy device
Primary purpose: TREATMENT

Brief summary: Two study arms - sham and treatment; There will be a cross over of the sham group to the treatment group at day 15.

Detailed description: This is a post market study. The active device will be the FDA cleared device used within its labeling. The sham group will receive an iTEAR device which looks identical to and makes noise similar to a fully functional iTEAR device but has a tip that does not vibrate. All subjects in the sham group will crossover to the treatment group after 2 two weeks and all patients will continue to 30 days.

The study will be conducted at up to 5 sites in the United States. It will enroll 30 subjects for 30 days.

This is a double-masked study with 10 subjects receiving sham and 20 subjects receiving treatment. The subjects and the examining investigators are masked to treatment until the crossover.

Eligibility criteria: Inclusion Criteria:

* \> 6hrs visual display terminal
* OSDI \> 13
* One of: SChirmer \< 10, One quadrant staining \> 2, or Meibomian Gland expression \<12

Exclusion Criteria:

* Opinion of investigator that subject not be in the study

Primary outcomes:
measure: Meibomian Gland change in expressibility
timeFrame: 14 days
measure: Corneal Staining
timeFrame: 14 days
measure: Basal tear output
timeFrame: 14 days
Secondary outcomes:
measure: Safety
timeFrame: 30 days
Other outcomes:
Locations:
city: Palo Alto
country: United States
facility: Fishman Vision
state: California
Study officials:
References:
Clinical trial NCT04323618: Investigation of Respiratory-related Tumour Motion in Liver Cancer Patients Undergoing SBRT Using Audiovisual Biofeedback
Official title: Investigation of Respiratory-related Tumour Motion in Liver Cancer Patients Undergoing Stereotactic Body Radiotherapy Treatment (SBRT) Using Audiovisual (AV) Biofeedback
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Lung Cancer
Lead sponsor: University of Sydney
Sponsor class: OTHER
First posted: 2020-03-26
Enrollment: 5
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DEVICE_FEASIBILITY

Brief summary: Investigation of respiratory-related tumour motion in liver cancer patients undergoing stereotactic body radiotherapy treatment (SBRT) using audiovisual (AV) biofeedback.


Eligibility criteria: Inclusion Criteria:

* Liver cancer patients, either primary hepatocellular carcinoma or liver metastases, eligible for stereotactic radiotherapy.
* \>18 years old
* Radio-opaque markers implanted (fiducials and/or surgical clips previously implanted in the liver)
* Able to give written informed consent and willingness to participate and comply with the study

Exclusion Criteria:

* Pregnant / lactating women

Primary outcomes:
measure: Improvement in reproducibility of respiratory-related tumour motion (via fiducial maker surrogacy) for liver cancer patients treated with the AV biofeedback respiratory guidance system.
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04488718: ESj- Powder Complete T&A Study
Official title: Evaluation of Tolerance and Acceptability of EnergieShake® Junior Powder Complete
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Child Nutrition Disorders
Child Malnutrition
Lead sponsor: Anaiah Healthcare Pvt Ltd
Sponsor class: INDUSTRY
Collaborators: name: Brighton and Sussex University Hospitals NHS Trust
name: Great Ormond Street Hospital for Children NHS Foundation Trust
name: The Leeds Teaching Hospitals NHS Trust
First posted: 2020-07-28
Enrollment: 18
Sex: ALL
Minimum age (years): 1
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The goal of this study is to gather data on the tolerance and acceptability of a new ONS (ESj-powder complete) in children currently taking ONS.

Detailed description: The goal of this study is to demonstrate the tolerance and acceptability of the test product when consumed by children who are currently prescribed (a similar) ONS. The data generated from this study will be submitted to the ACBS, who will consider it for reimbursement as a Food for Special Medical Purpose (FSMP) in the UK.

Eligibility criteria: Inclusion Criteria:

* \>1-18 years of age
* Children currently prescribed and consuming Oral Nutritional Supplements (ONS)
* Willingness to take part in the study, and consent to the study protocol signed by parent/guardian or older child (when appropriate)

Exclusion Criteria:

Participants requiring exclusive enteral tube feeding

* Participants on parenteral nutrition
* Participants with cow's milk or soy allergy or lactose intolerance
* Participants with galactosaemia
* Participants with a chronic renal or liver disease
* Participants who are acutely unwell

Primary outcomes:
measure: Acceptability & Tolerance: questionnaire
timeFrame: 7 days
measure: Gastrointestinal Tolerance
timeFrame: 7 days
Secondary outcomes:
Other outcomes:
Locations:
city: Brighton
country: United Kingdom
facility: Brighton & Sussex NHS Trust
city: Leeds
country: United Kingdom
facility: Leeds Children's Hospital,
city: London
country: United Kingdom
facility: Great Ormond Street Hospital Foundation Trust
Study officials:
References:
Clinical trial NCT04833218: Propranolol Versus Propranolol and Clonidine in Sympathetic Hyperactivity After Moderate Traumatic Brain Injury
Official title: Propranolol Versus Propranolol and Clonidine in Sympathetic Hyperactivity After Moderate Traumatic Brain Injury
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: EARLY_PHASE1
Conditions: Traumatic Brain Injury
Lead sponsor: Minia University
Sponsor class: OTHER
First posted: 2021-04-06
Enrollment: 90
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: evaluation of the effect of Propranolol versus propranolol and clonidine on decreasing sympathetic hyperactivity after moderate traumatic brain injury

Detailed description: measuring catecholamine levels after moderate traumatic brain injury after giving propranolol and clonidine

Eligibility criteria: Inclusion Criteria:

* GCS on admission between 9 and 12 age 18 up to 60 years both sexes

Exclusion Criteria:

* history of heart disease, cardiac arrhythmia and myocardial infarction diagnosis ofpreexisting brain dysfunction. impending brain herniation and craniotomy diagnosis of spinal cord injuries. diagnisis of severe liver and renal disease current use of beta blocker and or alpha agonist current using of intravenous vasopressor contraindication to enteral feeding and can not swallow pregnancy

Primary outcomes:
measure: catecholamine level on day 7
timeFrame: seven days
Secondary outcomes:
measure: mean arterial blood pressure every 4 hours herat rate every 4 hours temperature every 4 hours respiratory rate every 4 hours
timeFrame: 7 days
measure: Glascow coma scale
timeFrame: 7 days
Other outcomes:
Locations:
city: Minya
country: Egypt
facility: Faculty Of Medicine
Study officials:
affiliation: Professor
name: Amany Khairy, MD
role: STUDY_CHAIR
References:
Clinical trial NCT03412318: Evaluation of the Effect of Root Canal Preparation by TF and M-Pro on Post-Operative Pain After Single Visit Endodontic Treatment
Official title: Evaluation of the Effect of Root Canal Preparation by TF and M-Pro on Post-Operative Pain After Single Visit Endodontic Treatment: A Blinded Randomized Clinical Trial Therapeutic Study.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Acute Pulpitis
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2018-01-26
Enrollment: 48
Sex: ALL
Minimum age (years): 20
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A study to comparatively evaluate the post operative pain between root canal preparation by reciprocating file (TF) and full rotation file (M-Pro) in patients with single rooted teeth with acute irreversible pulpits.

Detailed description: Teeth with symptomatic irreversible pulpitis are selected according to the eligibility and exclusion criteria and patients are then randomized to receive treatment after using Twisted files or M-pro files. The treatment is done in single visit. The postoperative pain is then assessed using the Numerical Rating Scale 6,12, 24 and 48 hours post-instrumentation.

Eligibility criteria: Inclusion Criteria:

* Patients in good health (American Society of Anesthesiologists Class II or higher).
* Patients having symptomatic irreversible pulpitis in their single rooted teeth.
* Age range is between 20 and 60 years.
* Patients who can understand numerical rating scale (NRS).
* Patients able to sign informed consent.

Exclusion Criteria:

* Patients with positive percussion test.
* Patients having history of necrosis with or without apical pathosis.
* Patients have sinus tract or fistula extra oral or intraoral.
* Pregnant or mentally retarded patients.
* Teeth with grade 2 or 3 mobility.

Primary outcomes:
measure: Post-operative pain
timeFrame: 2 days
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Ahmad Almorad
Study officials:
References:
citation: Gambarini G, Testarelli L, De Luca M, Milana V, Plotino G, Grande NM, Rubini AG, Al Sudani D, Sannino G. The influence of three different instrumentation techniques on the incidence of postoperative pain after endodontic treatment. Ann Stomatol (Roma). 2013 Mar 20;4(1):152-5. doi: 10.11138/ads.0152. Print 2013 Jan.